Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael Kelner

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentPathology
    Address9300 Campus Point Drive #7721
    CA La Jolla 92037
    Phone858-657-5731
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Halogenated Alkenes and Microsomal GSH-transferases
      NIH/NIEHS R01ES013687Aug 8, 2006 - Apr 30, 2012
      Role: Principal Investigator
      ALTERATION OF ERCC GENE EXPRESSION IN VITRO AND IN VIVO
      NIH/NIA R01AG013153Aug 1, 1996 - Jul 31, 2000
      Role: Principal Investigator
      Coordinated Regulation of Antioxidant Enzymes
      NIH/NCI R01CA052310Apr 1, 1992 - Jun 30, 2006
      Role: Principal Investigator
      GENETIC INSIGHT INTO OXIDATIVE DAMAGE
      NIH/NIA R01AG010746Jan 15, 1992 - Dec 31, 1995
      Role: Principal Investigator
      GPX1 ENZYME REGULATION BY OXIDATIVE XENOBIOTICS
      NIH/NIEHS R01ES004989Jul 1, 1990 - Nov 30, 2004
      Role: Principal Investigator
      INHIBITION OF PARAQUAT OXYGEN-MEDIATED TOXICITY
      NIH/NIEHS K08ES000142Jul 1, 1985 - Jan 31, 1989
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Staake MD, Kashinatham A, McMorris TC, Estes LA, Kelner M. Hydroxyurea derivatives of irofulven with improved antitumor efficacy. Bioorg Med Chem Lett. 2016 Apr 1; 26(7):1836-8. PMID: 26922141.
        View in: PubMed
      2. Kelner M, Diccianni MB, Yu AL, Rutherford MR, Estes LA, Morgenstern R. Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue. Free Radic Biol Med. 2014 Apr; 69:167-71. PMID: 24486338.
        View in: PubMed
      3. Li K, Ku G, Yan M, Broome HE, Kelner M, Wang HY. A rare and unique case of aggressive IgE-? plasma cell myeloma in a 28-year-old woman presented initially as an orbital mass. Hum Pathol. 2012 Dec; 43(12):2376-84. PMID: 23084304.
        View in: PubMed
      4. McMorris TC, Chimmani R, Alisala K, Staake MD, Banda G, Kelner M. Structure-activity studies of urea, carbamate, and sulfonamide derivatives of acylfulvene. J Med Chem. 2010 Feb 11; 53(3):1109-16. PMID: 20067264.
        View in: PubMed
      5. Stadalman KA, Kelner M, Box K, Dominguez A, Rigby JF. Stability of levothyroxine sodium 0.4 microg/mL in 0.9% sodium chloride injection. Prog Transplant. 2009 Dec; 19(4):354-6; quiz 357. PMID: 20050459.
        View in: PubMed
      6. Kelner M, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec; 63(1):19-26. PMID: 18305940.
        View in: PubMed
      7. Kelner M, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs. 2008 Oct; 26(5):407-15. PMID: 18227973.
        View in: PubMed
      8. Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner M, Hardiman G, Bélanger A, Tukey RH. Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem. 2008 Mar 21; 283(12):7901-11. PMID: 18180294.
        View in: PubMed
      9. McMorris TC, Chimmani R, Gurram M, Staake MD, Kelner M. Synthesis and antitumor activity of amine analogs of irofulven. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6770-2. PMID: 17977722.
        View in: PubMed
      10. Kelner M, Bagnell RD, Morgenstern R. Structural organization of the murine microsomal glutathione S-transferase gene (MGST1) from the 129/SvJ strain: identification of the promoter region and a comprehensive examination of tissue expression. Biochim Biophys Acta. 2004 May 25; 1678(2-3):163-9. PMID: 15157743.
        View in: PubMed
      11. McMorris TC, Staake MD, Kelner M. Synthesis and biological activity of enantiomers of antitumor irofulven. J Org Chem. 2004 Feb 6; 69(3):619-23. PMID: 14750783.
        View in: PubMed
      12. McMorris TC, Cong Q, Kelner M. Structure-activity relationship studies of illudins: analogues possessing a spiro-cyclobutane ring. J Org Chem. 2003 Dec 12; 68(25):9648-53. PMID: 14656090.
        View in: PubMed
      13. Ekström L, Lyrenäs L, Jakobsson PJ, Morgenstern R, Kelner M. Basal expression of the human MAPEG members microsomal glutathione transferase 1 and prostaglandin E synthase genes is mediated by Sp1 and Sp3. Biochim Biophys Acta. 2003 Jun 19; 1627(2-3):79-84. PMID: 12818425.
        View in: PubMed
      14. McMorris TC, Moon SS, Kelner M. Reaction of irofulven with zinc and acid. J Nat Prod. 2003 Feb; 66(2):310-2. PMID: 12608875.
        View in: PubMed
      15. Jaspers NG, Raams A, Kelner M, Ng JM, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JH. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst). 2002 Dec 5; 1(12):1027-38. PMID: 12531012.
        View in: PubMed
      16. McMorris TC, Kashinatham A, Lira R, Rundgren H, Gantzel PK, Kelner M, Dawe R. Sesquiterpenes from Omphalotus illudens. Phytochemistry. 2002 Oct; 61(4):395-8. PMID: 12377232.
        View in: PubMed
      17. Kelner M, McMorris TC, Rojas RJ, Trani NA, Velasco TR, Estes LA, Suthipinijtham P. Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs. 2002 Aug; 20(3):271-9. PMID: 12201490.
        View in: PubMed
      18. Kelner M, McMorris TC, Rojas RJ, Trani NA, Estes L. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol. 2002 May; 49(5):412-8. PMID: 11976836.
        View in: PubMed
      19. Kelner M, Bagnell RD, Montoya MA, Lanham KA. Structural organization of the human gastrointestinal glutathione peroxidase (GPX2) promoter and 3'-nontranscribed region: transcriptional response to exogenous redox agents. Gene. 2000 May 2; 248(1-2):109-16. PMID: 10806356.
        View in: PubMed
      20. Kelner M, Bagnell RD, Montoya MA, Estes LA, Forsberg L, Morgenstern R. Structural organization of the microsomal glutathione S-transferase gene (MGST1) on chromosome 12p13.1-13.2. Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress. J Biol Chem. 2000 Apr 28; 275(17):13000-6. PMID: 10777602.
        View in: PubMed
      21. Kelner M, Montoya MA. Structural organization of the human glutathione reductase gene: determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun. 2000 Mar 16; 269(2):366-8. PMID: 10708558.
        View in: PubMed
      22. Kelner M, McMorris TC, Estes LA, Oval MY, Rojas RJ, Lynn JR, Lanham KA, Samson KM. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs. 2000 Mar; 11(3):217-24. PMID: 10831281.
        View in: PubMed
      23. Kelner M, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol. 1999; 44(3):235-40. PMID: 10453725.
        View in: PubMed
      24. Kelner M, Montoya MA. Structural organization of the human selenium-dependent phospholipid hydroperoxide glutathione peroxidase gene (GPX4): chromosomal localization to 19p13.3. Biochem Biophys Res Commun. 1998 Aug 10; 249(1):53-5. PMID: 9705830.
        View in: PubMed
      25. Kelner M, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R. Characterization of acylfulvene histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol. 1998; 41(3):237-42. PMID: 9443641.
        View in: PubMed
      26. McMorris TC, Yu J, Hu Y, Estes LA, Kelner M. Design and Synthesis of Antitumor Acylfulvenes. J Org Chem. 1997 May 02; 62(9):3015-3018. PMID: 11671671.
        View in: PubMed
      27. Kelner M, Estes L, Rutherford M, Uglik SF, Peitzke JA. Heterologous expression of carbonyl reductase: demonstration of prostaglandin 9-ketoreductase activity and paraquat resistance. Life Sci. 1997; 61(23):2317-22. PMID: 9408054.
        View in: PubMed